News

Kenox Pharmaceuticals Announces Strategic Collaboration with Lactiga

Back

Princeton, NJ – Kenox Pharmaceuticals Inc (Kenox), is proud to partner with Lactiga to develop novel mucosal-targeted sIgA therapies for immunodeficient patients. Supported by a multi-million-dollar NIH STTR grant, the partnership will accelerate preclinical development of intranasal biologics. This initiative combines Kenox’s inhalation delivery expertise with Lactiga’s breakthrough sIgA platform technology. Together, we aim to bring transformative, first-in-class therapies to patients with compromised immune systems.

For more information, see our recent news Click here.

If you would like to discuss your project or learn more about our capabilities, please reach out to us at bd@kenoxpharma.us.